Status:
COMPLETED
Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes
Lead Sponsor:
Novartis
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-78 years
Phase:
PHASE3
Brief Summary
This is a 52-week extension to a study to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to metformin in lowering overall blood glucose levels in people with type 2 ...
Eligibility Criteria
Inclusion
- Only patients successfully completing study CLAF237A2309 are eligible
- Written informed consent
- Ability to comply with all study requirements
Exclusion
- Premature discontinuation from CLAF237A2309
- Other protocol-defined exclusion criteria may apply
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
August 1 2006
Estimated Enrollment :
530 Patients enrolled
Trial Details
Trial ID
NCT00138567
Start Date
January 1 2005
End Date
August 1 2006
Last Update
November 18 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
East Hanover, New Jersey, United States, 07936
2
Novartis Investigative site
Investigative Centers, Germany